Compare OCGN & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCGN | TOI |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 327.6M |
| IPO Year | 2014 | N/A |
| Metric | OCGN | TOI |
|---|---|---|
| Price | $1.58 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $6.00 |
| AVG Volume (30 Days) | ★ 3.8M | 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.88 | $28.51 |
| Revenue Next Year | N/A | $25.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.60 |
| 52 Week High | $1.96 | $4.88 |
| Indicator | OCGN | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 57.47 | 38.35 |
| Support Level | $1.38 | $2.32 |
| Resistance Level | $1.47 | $2.73 |
| Average True Range (ATR) | 0.09 | 0.22 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 94.64 | 40.35 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.